



## OPEN ACCESS

APPROVED BY  
Frontiers Editorial Office,  
Frontiers Media SA, Switzerland

\*CORRESPONDENCE  
Ariel E. Feldstein  
✉ [afeldstein@health.ucsd.edu](mailto:afeldstein@health.ucsd.edu)

RECEIVED 08 July 2024  
ACCEPTED 10 July 2024  
PUBLISHED 19 December 2024

CITATION  
Santoro N and Feldstein AE (2024)  
Corrigendum: The role of oxidized  
lipid species in insulin resistance  
and NASH in children.  
*Front. Endocrinol.* 15:1461564.  
doi: 10.3389/fendo.2024.1461564

COPYRIGHT  
© 2024 Santoro and Feldstein. This is an  
open-access article distributed under the terms  
of the [Creative Commons Attribution License  
\(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction  
in other forums is permitted, provided the  
original author(s) and the copyright owner(s)  
are credited and that the original publication  
in this journal is cited, in accordance with  
accepted academic practice. No use,  
distribution or reproduction is permitted  
which does not comply with these terms.

# Corrigendum: The role of oxidized lipid species in insulin resistance and NASH in children

Nicola Santoro<sup>1,2,3</sup> and Ariel E. Feldstein<sup>4,5\*</sup>

<sup>1</sup>Department of Pediatrics, Kansas Medical Center, Kansas City, KS, United States, <sup>2</sup>Department of Medicine and Health Sciences, "V.Tiberio" University of Molise, Campobasso, Italy, <sup>3</sup>Department of Pediatrics, Yale University School of Medicine, New Haven, CT, United States, <sup>4</sup>Department of Pediatrics, University of California San Diego, La Jolla, CA, United States, <sup>5</sup>Global Drug Discovery, Novo Nordisk, Copenhagen, Denmark

## KEYWORDS

lipids, PUFA (polyunsaturated fatty acids), NAFLD (nonalcoholic fatty liver disease), diabetes, children

## A Corrigendum on

### The role of oxidized lipid species in insulin resistance and NASH in children

By Santoro N and Feldstein AE (2022). *Front. Endocrinol.* 13:1019204. doi: 10.3389/fendo.2022.1019204

In the published article, there was an error regarding the affiliations for Ariel E. Feldstein. As well as having affiliation 4, they should also have "Global Drug Discovery, Novo Nordisk, Copenhagen, Denmark".

In the published article, there was an error in the **Conflicts of interest**, and a declaration regarding author Ariel E. Feldstein was erroneously excluded.

The corrected **Conflicts of interest** section appears below.

"AF is an employee and stockholder of Novo Nordisk.

The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."

The author apologizes for this error and states that this does not change the scientific conclusions of the article in any way. The original article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.